ライフサイエンスコーパス: active group

1 improvement in the balance step test in the active group).

2 increase in IgE+ cells in patients from the active group.

3 percentage of responders were greater in the active group.

4 nt increase of mites-specific IgG4 levels in active group.

5 was no significant difference between the 2 active groups.

6 ue to adverse effects was more common in the active groups.

7 a, and ability to predictably organize redox-active groups.

8 nt decrease in FeNO level comparable in both active groups.

9 n a flavin cofactor and a disulfide as redox-active groups.

10 y weight and activity groups, with the least-active group (15.7 +/- 9.9 min MVPA/d, 6062 +/- 1778 ste

11 body weight (86.3 +/- 13.2 kg) and the most-active group (174.5 +/- 60.5 min MVPA/d, 10260 +/- 3087

12 Thus, (+)-9 is the first orally active group 2 mGluR agonist described thus far and is a

13 ation due to adverse events was 4% (7 in the active group, 2 in the placebo group).

14 ely depressed (mean EPDS score 21.8 [SD 3.0] active group, 21.3 [2.9] placebo group; SADS scores, 66.

15 in the number of circulating bacteria in the active group (3.5 x 10(4) vs. 3.1 x 10(3) colony-forming

16 -HRQL score was significantly greater in the active group (56%) compared with the sham group (18.5%;

17 on neuropsychological measures (47.7% in the active group; 63.1% in younger participants).

18 M) performance significantly improved in the active group after GVC (p=0.008), and remained stable in

19 ion scores were significantly reduced in the active group after six months.

20 rimary endpoint was -0.028 (SD 0.453) in the active group and -0.108 (0.528) in the control group; es

21 r the start of treatment were -212.5 for the active group and -97.8 for the placebo group (P = .0040)

22 sitized, and 284 were randomized (146 to the active group and 138 to the placebo group).

23 31 patients in the active group and 29 in the control group completed the s

24 nts occurred in 34 (22%) participants in the active group and 30 (19%) in control group (p=0.487), no

25 xperienced a confirmed CVD event (406 in the active group and 390 in the placebo group).

26 Forty-nine patients in the active group and 53 in the sham group underwent 12 weeks

27 For vitamin C, there were 97 cases in the active group and 96 in the placebo group (HR, 0.99; 95%

28 Seventeen of 27 patients in active group and none of 13 patients in control group (P

29 (24 of 39 participants; 95% CI 45-78) in the active group and none of the control group after the fir

30 penultimate phosphodiester bond by providing active groups and coordination bonds to the RNAP active

31 trated a global treatment effect between the active groups and placebo, hence confirming the study dr

32 in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent di

33 8 times as high for individuals in the least-active group as for those in the middle activity group.

34 Relative dropout rates in placebo and active groups as well as reasons for dropout were also a

35 r 20-mers), of the d or l configuration with active groups at the N or C termini, were bound at 5-32

36 sIgG4 raised only in active group (Bet v 1: P = 0.054, Gly m 4: P = 0.037), a

37 ssessment showed a tendency in favour of the active group but did not reach statistical significance.

38 There was more vomiting in the active group but no other important differences were det

39 without disability among the most physically active group compared with sedentary adults (adjusted od

40 th an additional stepwise improvement in the active groups compared to placebo, which was significant

41 IgG1 increased significantly in all active groups compared to placebo.

42 symptom score significantly decreased in all active groups compared with placebo (-18.8% for placebo

43 For 24 weeks after treatment, the active group continued unsupervised home exercise while

44 The caries-active group exhibited significantly lower degrees of sa

45 cluded all operated patients: eight from the active group, four from the sham group who were submitte

46 ter bond released a fraction of the Fc redox active groups from the electrode surface, decreasing the

47 and the burial depth of the voltammetrically active groups from the surface concentration dependence

48 Among participants with plaque, the most active group (>2000 MET-min/wk) had a lower prevalence o

49 Ten percent (15/154) of infants in the active group had AD compared with 19% (27/145, P = .030)

50 At 54 months, 2 additional patients in the active group had become responders.

51 %) in the placebo group, and 96 (36%) in the active group (hazard ratio 1.11, 95% CI 0.83-1.49; p=0.4

52 ncy hospital attendance was 45% lower in the active group (hazard ratio, 0.55; 95% confidence interva

53 found between the stable moderate and always active groups (hazard ratio = 1.24, 95% confidence inter

54 The most active group, however, had a more benign composition of

55 ngstrom crystal structure of a catalytically active group I intron splicing intermediate containing t

56 nts in the RNA and yielded the catalytically active group I intron structure.

57 stitutions grossly disrupt the catalytically-active group I intron tertiary structure, and that CYT-1

58 This demonstrates that only one redox-active group (i.e., the covalent FAD cofactor) is involv

59 l, hydrodynamic and structural properties of active group II intron RNP particles (+A) isolated from

60 drug that delivers to the brain BCI-632, the active Group II mGluR antagonist metabolite.

61 alues were significantly lower in the caries-active group in comparison with the caries-free and cari

62 espectively, show that FAD is the only redox-active group in nikD.

63 lysing oxidation and reduction of chemically active groups in surface-anchored N-heterocyclic carbene

64 eted with essential contributions from other active groups in the field.

65 owever, sRaw was significantly better in the active group (kiloPascal/second, geometric mean [95% CI]

66 ; 95% CI, 1.28-9.97) compared with the least active group (<1000 MET-min/wk).

67 e first 8-week intervention was 0.89 for the active group (n = 113) and -0.06 for the placebo group (

68 The active group (n = 131) received 250 mg (weight 18-35.9 k

69 18.5% (95% CI, 12.5%-24.1%; P < .001) in the active group (n = 150) over that observed in the placebo

70 The active group (n = 87) received 250 mg (weight <40 kg) or

71 pants screened were randomly assigned to the active group (n=153) or control group (n=158).

72 ubiquitous macromolecule that serves as the active group of proteins involved in many cellular proce

73 Incident AF was more frequent in the active groups of both trials, reaching statistical signi

74 yl group on SAM via amide bond and unreacted active groups of LC-SPDP were blocked using 1% ethanol a

75 we show that partial mobility restriction of active groups of the drug molecule suggests why this car

76 ipid peroxidation by direct interaction with active groups of these lipids and could also contribute

77 teractions arising from densely packed redox-active groups, only when prepared as thin films.

78 ma exacerbation to receive mite-impermeable (active group) or control (placebo group) bed encasings.

79 percentage of CD4(+)CD25(+) was lower in the active group (P < .05) and correlated with changes in CD

80 e ratings than in low-calorie ratings in the active group (P = 0.001).

81 9 ng/mL in the controls vs. 2.1 ng/mL in the active group (p =.05).

82 men was 20% to 35% higher than in the 2 less active groups (P:<0.01).

83 t one measure (41.3% of declines occurred in active group participants; 63.0% in older participants r

84 sity; no Pa was detected on Day 28 in 8 of 8 active group patients compared with 1 of 13 placebo grou

85 of the polymer chains are terminated by the active groups (Ph-C(=S)-S-) derived from RAFT agents, an

86 Women in the physically active group (ratio of TEE to RMR = 1.89 +/- 0.08) gaine

87 The active group received aerosolized FP once daily for 5 da

88 Nineteen of 46 patients (41%) in the active group reported 26 mild adverse effects and 7 of 4

89 itizations to mites, while 3 patients in the active group showed neosensitization to shrimp with nega

90 of eczema decreased in both groups, but the active group showed significantly greater improvements i

91 Both active groups showed significant improvement in quality

92 ct to the other two subtypes), with the TP53-active group showing better prognosis.

93 In the high Mr enzyme, a third redox active group shuttles the reducing equivalent from the a

94 months, significantly fewer children in the active group than in the placebo group had attended the

95 ance with exacerbations was 27% lower in the active group than in the placebo group, but this did not

96 len exposure was in all seasons lower in the active group than in the placebo group, with relative di

97 PPI therapy was higher among patients in the active group than in the sham group by intention-to-trea

98 and oxygen delivery tended to be greater in active groups than in controls.

99 or photosensitivity were more common in the active groups than with placebo.

100 This creates a new surface with more "active" groups that can form new hydroxyl bridges.

101 For the active group, the baseline mean (SD) visual analog scale

102 g defects act synergistically with the polar active groups to enhance the enzymatic electrostatics.

103 ing moieties or chemical modifications using active groups to integrate different contrast properties

104 84% (95% CI 70-93) of the active group tolerated daily ingestion of 800 mg protein

105 ilter, which is positively charged with DEAE active groups, traps low-molecular-weight DNA fragments.

106 e induction are dependent on a catalytically active Group V sPLA(2).

107 change of -9.0 (IQR: -13 to -5) days in the active group versus +3.0 (IQR: -1.0 to + 5.0) days in th

108 pH < 4 was significantly improved within the active group versus baseline (7 vs 10, 18%, P < .001) bu

109 cal (20% vs 21%) morbidity were found in the active group versus the placebo group.

110 the observed data (full analysis set) in the active groups vs the placebo group were 0.09 (95% CI, 0.

111 ne mean (SD) physical function score for the active group was 32.3 (9.2) and the week-13 score was 27

112 In the active group, we provided multifaceted educational inter

113 ecies found to be overabundant in the caries-active group were Actinomyces sp. strain B19SC, Streptoc

114 The most common adverse events in the active group were headache (17%), fatigue (16%), and nau

115 Children in the active group were significantly more frequently sensitiz

116 bo group was discontinued and thereafter the active groups were continued, and participants initially

117 transcription systems contain electrophilic active groups, whereas lycopene and nonxanthophylic caro

118 agent that combines two complementary chemo-active groups within a single molecular architecture, we